Your shopping cart is currently empty

hCAI/II-IN-6 is a selective and orally active inhibitor of human carbonic anhydrase (CA). hCAI/II-IN-6 inhibited hCA I, hCA II, hCA VII, and hCA XII with Ki values of 220, 4.9, 6.5, and >50,000 nM. hCAI/II-IN-6 showed anticonvulsant activity in vivo. hCAI/II-IN-6 can be used to study epilepsy. hCAI/II-IN-6 showed anticonvulsant activity in vivo. hCAI/II-IN-6 can be used to study epilepsy.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $41 | In Stock | In Stock | |
| 10 mg | $65 | In Stock | In Stock | |
| 25 mg | $119 | In Stock | In Stock | |
| 50 mg | $178 | In Stock | In Stock | |
| 100 mg | $278 | - | In Stock |
| Description | hCAI/II-IN-6 is a selective and orally active inhibitor of human carbonic anhydrase (CA). hCAI/II-IN-6 inhibited hCA I, hCA II, hCA VII, and hCA XII with Ki values of 220, 4.9, 6.5, and >50,000 nM. hCAI/II-IN-6 showed anticonvulsant activity in vivo. hCAI/II-IN-6 can be used to study epilepsy. hCAI/II-IN-6 showed anticonvulsant activity in vivo. hCAI/II-IN-6 can be used to study epilepsy. |
| Targets&IC50 | CA (human):220 nM(Ki ), CA XII (human):>50000 nM(Ki ), CA II (human):4.9 nM(Ki ), CA VII (human):6.5 nM(Ki ) |
| In vitro | hCAI/II-IN-6 (0-50 μM) inhibits the activities of hCA I, hCA II, hCA VII, and hCA XII, with Ki values of 220 nM, 4.9 nM, 6.5 nM, and >50000 nM, respectively.[1] |
| In vivo | In vivo, hCAI/II-IN-6 (30-100mg/kg; i.p. once; Swiss albino mice) provided seizure attenuation and good anticonvulsant effect and showed an ED 50 of 13.7mg/kg in anticonvulsant quantification study. [1] In vivo, hCAI/II-IN-6 (30 mg/kg; p.o.; once; Swiss albino mice) has been observed to possess anti-MES (maximal electroshock seizure) activity.[1] |
| Molecular Weight | 388.48 |
| Formula | C19H24N4O3S |
| Cas No. | 694466-00-7 |
| Smiles | NS(=O)(=O)c1ccc(NC(=O)CN2CCN(Cc3ccccc3)CC2)cc1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 225 mg/mL (579.18 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.